Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B. subtilis for IBS-D
NCT06612411Phase 1Recruiting
- Sponsor
- Jinling Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing B. subtilis intervention with Placebo capsules (2 arms). Primary endpoint: IBS Symptom Severity Scale at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
bacillus subtilis
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT06612411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612411.